Humana (HUM) is higher in Tuesday trading as investors react to a bullish shift in analyst sentiment: Jefferies upgraded the stock to Buy, arguing Humana’s Medicare Advantage “Stars diversification” and contract mix support meaningfully better earnings power than the market is pricing in. The upgrade narrative is centered on the view that 2026–2027 EPS can land above consensus, helping drive a rebound after the stock’s earlier selloff tied to a downbeat 2026 outlook. (seekingalpha.com)

Humana’s 2026 outlook has been the key overhang: the company introduced FY2026 GAAP EPS guidance of at least $8.89 (and adjusted EPS guidance of at least $9.00), which reset expectations and amplified concerns about Medicare Advantage margin pressure and Star Ratings-related headwinds. Today’s move reflects a partial “relief rally” as some investors lean into the idea that the trough year could be less severe and that the earnings recovery path into 2027 is being underappreciated. (fortune.com)

Near-term, traders will look for any additional guidance commentary in upcoming investor discussions and for signals that medical cost trends are stabilizing. Longer-term, the stock remains highly sensitive to Medicare Advantage policy and reimbursement updates, Star Ratings outcomes, and evidence that Humana can execute pricing and benefit design without sacrificing membership and margin. (tipranks.com)